Baidu
map

Circ Heart Fail:小剂量阿司匹林或使心衰患者获益

2014-02-11 晓静 编译 医学论坛网

2月3日在线发表于《循环·心力衰竭》(Circulation: Heart Failure)杂志的一项研究表明,在心力衰竭患者中,每日给予小剂量阿司匹林(75 mg/d)可使其多年死亡率降低42%。无论患者有无进行标准应用阿司匹林的适应证,它均可延长患者的生存期,这些患者包括缺血性心脏病、外周血管疾病或卒中患者。虽然不同剂量的阿司匹林均可改善心力衰竭患者的住院率,但给予患者的阿司匹林剂量>7

2月3日在线发表于《循环·心力衰竭》(Circulation: Heart Failure)杂志的一项研究表明,在心力衰竭患者中,每日给予小剂量阿司匹林(75 mg/d)可使其多年死亡率降低42%。无论患者有无进行标准应用阿司匹林的适应证,它均可延长患者的生存期,这些患者包括缺血性心脏病、外周血管疾病或卒中患者。虽然不同剂量的阿司匹林均可改善心力衰竭患者的住院率,但给予患者的阿司匹林剂量>75 mg/d则不存在上述生存获益。

该研究结果与之前的几项研究结果相反,在那些随机化研究中,有研究者发现应用华法林和阿司匹林应用者有更多的出血事件且并未观察到临床益处,还有研究者发现阿司匹林和华法林似乎均不能防止不良事件的发生。但这些研究中,患者均是接受了2—4倍的小剂量阿司匹林。这表明,小剂量阿司匹林在诊断为心力衰竭患者中的二级预防中可能发挥着持续作用,并需要在这些患者中对小剂量阿司匹林进行更多的研究。

该回顾性研究共纳入1476例受试者,对其中位随访2.15年(1天至12年),基线时有892例(60%)患者被处方了阿司匹林。在这些患者中,91%接受了小剂量阿司匹林治疗,剩余患者接受了更高剂量的阿司匹林治疗。给予18.4%阿司匹林组患者其他抗血小板药如氯吡格雷,同时这些患者27.8%额外应用了华法林,且有2.1%的患者接受了双重抗血小板治疗和华法林。研究结果如下表所见。

小剂量和大剂量阿司匹林以及无阿司匹林治疗的患者终点事件危险比(95% CI)

终点事件

阿司匹林:小剂量vs无

阿司匹林:小vs大剂量

阿司匹林:大剂量vs 无

死亡率

0.58 (0.46–0.74)

0.57 (0.35–0.92)

0.98 (0.59–1.63)

心力衰竭入院

0.70 (0.54–0.90)

1.27 (0.70–2.30)

0.50 (0.27–0.92)

原始出处:

Low-Dose Aspirin Ups Survival in Heart Failure: Community-Based Cohort Study.Medscape February 07, 2014

Bermingham M, Shanahan MK, O'Connell E, Dawkins I, Miwa S, O'Hanlon R, Gilmer J, McDonald K, Ledwidge M.Aspirin Use In Heart Failure: Is Low Dose Therapy Associated With Mortality And Morbidity Benefits In A Large Community Population?Circ Heart Fail. 2014 Feb 3. 


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2043589, encodeId=869f2043589cd, content=<a href='/topic/show?id=a9c2469e327' target=_blank style='color:#2F92EE;'>#小剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46973, encryptionId=a9c2469e327, topicName=小剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b3e473, createdName=pyaili, createdTime=Thu Mar 27 07:38:00 CST 2014, time=2014-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971227, encodeId=4f8f19e1227c4, content=<a href='/topic/show?id=1104469e552' target=_blank style='color:#2F92EE;'>#小剂量阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46975, encryptionId=1104469e552, topicName=小剂量阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ee7414, createdName=lanyan20020086, createdTime=Tue Nov 04 21:38:00 CST 2014, time=2014-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355826, encodeId=1446135582625, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Feb 13 02:38:00 CST 2014, time=2014-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373263, encodeId=eccf13e3263aa, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Feb 13 02:38:00 CST 2014, time=2014-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562206, encodeId=eb9515622064c, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Feb 13 02:38:00 CST 2014, time=2014-02-13, status=1, ipAttribution=)]
    2014-03-27 pyaili
  2. [GetPortalCommentsPageByObjectIdResponse(id=2043589, encodeId=869f2043589cd, content=<a href='/topic/show?id=a9c2469e327' target=_blank style='color:#2F92EE;'>#小剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46973, encryptionId=a9c2469e327, topicName=小剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b3e473, createdName=pyaili, createdTime=Thu Mar 27 07:38:00 CST 2014, time=2014-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971227, encodeId=4f8f19e1227c4, content=<a href='/topic/show?id=1104469e552' target=_blank style='color:#2F92EE;'>#小剂量阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46975, encryptionId=1104469e552, topicName=小剂量阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ee7414, createdName=lanyan20020086, createdTime=Tue Nov 04 21:38:00 CST 2014, time=2014-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355826, encodeId=1446135582625, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Feb 13 02:38:00 CST 2014, time=2014-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373263, encodeId=eccf13e3263aa, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Feb 13 02:38:00 CST 2014, time=2014-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562206, encodeId=eb9515622064c, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Feb 13 02:38:00 CST 2014, time=2014-02-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2043589, encodeId=869f2043589cd, content=<a href='/topic/show?id=a9c2469e327' target=_blank style='color:#2F92EE;'>#小剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46973, encryptionId=a9c2469e327, topicName=小剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b3e473, createdName=pyaili, createdTime=Thu Mar 27 07:38:00 CST 2014, time=2014-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971227, encodeId=4f8f19e1227c4, content=<a href='/topic/show?id=1104469e552' target=_blank style='color:#2F92EE;'>#小剂量阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46975, encryptionId=1104469e552, topicName=小剂量阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ee7414, createdName=lanyan20020086, createdTime=Tue Nov 04 21:38:00 CST 2014, time=2014-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355826, encodeId=1446135582625, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Feb 13 02:38:00 CST 2014, time=2014-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373263, encodeId=eccf13e3263aa, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Feb 13 02:38:00 CST 2014, time=2014-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562206, encodeId=eb9515622064c, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Feb 13 02:38:00 CST 2014, time=2014-02-13, status=1, ipAttribution=)]
    2014-02-13 一叶知秋
  4. [GetPortalCommentsPageByObjectIdResponse(id=2043589, encodeId=869f2043589cd, content=<a href='/topic/show?id=a9c2469e327' target=_blank style='color:#2F92EE;'>#小剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46973, encryptionId=a9c2469e327, topicName=小剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b3e473, createdName=pyaili, createdTime=Thu Mar 27 07:38:00 CST 2014, time=2014-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971227, encodeId=4f8f19e1227c4, content=<a href='/topic/show?id=1104469e552' target=_blank style='color:#2F92EE;'>#小剂量阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46975, encryptionId=1104469e552, topicName=小剂量阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ee7414, createdName=lanyan20020086, createdTime=Tue Nov 04 21:38:00 CST 2014, time=2014-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355826, encodeId=1446135582625, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Feb 13 02:38:00 CST 2014, time=2014-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373263, encodeId=eccf13e3263aa, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Feb 13 02:38:00 CST 2014, time=2014-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562206, encodeId=eb9515622064c, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Feb 13 02:38:00 CST 2014, time=2014-02-13, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2043589, encodeId=869f2043589cd, content=<a href='/topic/show?id=a9c2469e327' target=_blank style='color:#2F92EE;'>#小剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46973, encryptionId=a9c2469e327, topicName=小剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b3e473, createdName=pyaili, createdTime=Thu Mar 27 07:38:00 CST 2014, time=2014-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971227, encodeId=4f8f19e1227c4, content=<a href='/topic/show?id=1104469e552' target=_blank style='color:#2F92EE;'>#小剂量阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46975, encryptionId=1104469e552, topicName=小剂量阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ee7414, createdName=lanyan20020086, createdTime=Tue Nov 04 21:38:00 CST 2014, time=2014-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355826, encodeId=1446135582625, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Feb 13 02:38:00 CST 2014, time=2014-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373263, encodeId=eccf13e3263aa, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Feb 13 02:38:00 CST 2014, time=2014-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562206, encodeId=eb9515622064c, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Feb 13 02:38:00 CST 2014, time=2014-02-13, status=1, ipAttribution=)]

相关资讯

ESC 2013:RLX030显著改善急性心力衰竭(AHF)各亚组症状和死亡率

诺华(Novartis)9 月2日在2013年欧洲心脏病学会年会(ESC 2013)上,公布了有关实验性药物RLX030(serelaxin)III期RELAX-AHF研究新的分析数据。数据表明,在横跨急性心力衰竭 (AHF)患者多个亚组中,RLX030持续地改善了患者的症状,并降低了全因死亡率(all-cause mortality)。这些数据同时也发表于《欧洲心脏杂志》(E

BNP在心力衰竭中的诊治进展

近日,在2013中国心脏大会上,山东大学齐鲁医院季小平教授作了题为《BNP在心力衰竭中的诊治进展》的报告。经临床验证,血浆N末端B型钠尿肽(NT-proBNP)是目前管理心衰疾病的最佳生化指标;尤其在心衰的鉴别诊断、危险评级、预后判断和治疗监测上有重大意义。NT-proBNP虽然与B型尿钠肽(BNP)在临床意义上相近,但是在稳定性、抗干扰能力,以及对早期/轻度心脏功能不全的监测等方面具有明显优势,

ESC 2013:松弛素对不同特征的心力衰竭患者的主要临床终点具有一致性

研究要点:1.急性心力衰竭的住院率和死亡率很高。2.松弛素可以改善心力衰竭患者的呼吸困难症状。3.最新的一项研究表明,松弛素对不同亚群的心衰患者的临床终点具有一致性。心力衰竭患者的住院率和死亡率很高。然而,治疗方法在最近几十年也没有改变,新的治疗方法的临床试验阶段也没显示出优势。Serelaxin是人松弛素2的重组体,给急性心力衰竭患者注射后,呼吸困难的症状有所改善。由于心力衰竭入院的病人的情况和

ESC 2013:无晚期心力衰竭症状的患者心脏再同步化能明显获益(MADIT-CRT研究)

  背景: MADIT-CRT研究显示,心脏再同步治疗除颤器(CRT-D)能显著降低入选研究前至少3个月伴有轻度心力衰竭(HF)症状(NYHA 分级为I级或II级)患者的HF或死亡风险。该研究旨在评估CRT-D对入选研究前既往任何时间伴有晚期HF症状病史的患者的益处。   方法:于入选研究前任意时间均无晚期HR病史(NYHA分级≥III级或既往曾因HF恶化而住院)的患者(I组)及既往伴有

葛均波:心力衰竭体液潴留治疗新进展

心力衰竭治疗面临的困局心力衰竭(心衰)是21世纪心血管领域的三大疾病之一,自上世纪80年代起,冠心病死亡率逐步下降,而由心衰导致的住院率和死亡率却在不断攀升。社会的老龄化也将使这个问题更严重。预计在2015~2025年间,因心衰所产生的医疗费用也会急剧增加。因此,我们将要面临的是一个极大的挑战。临床上,患者因心衰首次急诊住院后,其中约1/4的患者在一个月之内将会再次入院;约1/2的患者在半年之

心脏"降落伞"挽救心力衰竭患者

北京大学第一医院心内科霍勇教授完成国内首例经皮心室重建术 心脏里也能安装“降落伞”?这不是神话,日前北京大学第一医院(北大医院)心内科在科主任霍勇教授带领下于2013年10月9日在国内率先通过微创介入的方法在两名陈旧前壁心肌梗死合并室壁瘤患者的心脏内植入了“降落伞”,改善了他们的心脏功能,完成了我国首例经皮心室重建术,实现了国内在该项技术零的突破。 降落

Baidu
map
Baidu
map
Baidu
map